Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ced.14761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between the systemic immune-inflammation index and sarcopenia in older adults: a cross-sectional study.
BMC Geriatr
January 2025
Faculty of Medicine, Department of Geriatric Medicine, Gazi University, Ankara, 06560, Turkey.
Background: Chronic inflammation is increasingly recognized as a crucial contributor to sarcopenia pathogenesis, but accurate diagnosis remains a challenge.
Aim: Our study aims to investigate the relationship between sarcopenia and the Systemic Immune-Inflammation Index (SII), a comprehensive indicator of inflammation.
Methods: This cross-sectional study enrolled 632 patients.
Exploring the comorbidity mechanisms between atherosclerosis and hashimoto's thyroiditis based on microarray and single-cell sequencing analysis.
Sci Rep
January 2025
Cardiology Department, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China.
Atherosclerosis (AS) is a chronic vascular disease characterized by inflammation of the arterial wall and the formation of cholesterol plaques. Hashimoto's thyroiditis (HT) is an autoimmune disorder marked by chronic inflammation and destruction of thyroid tissue. Although previous studies have identified common risk factors between AS and HT, the specific etiology and pathogenic mechanisms underlying these associations remain unclear.
View Article and Find Full Text PDFIlluminating the impact of CD38-induced adenosine formation in B-cell lymphoma.
Sci Rep
January 2025
Department of Clinical and Chemical Pathology, Ain shams University, Cairo, Egypt.
The expression of CD38 by cancer cells may mediate an immune-suppressive effect by producing Extracellular Adenosine (ADO) acting through G-protein-coupled cell surface receptors on cellular components and tumor cells. This can increase PD-1 expression and interaction with PD-L1, suppressing CD8 + cytotoxic T cells. This study examines the impact of heightened CD38 expression and extracellular ADO on various hematological and clinical parameters in patients with mature B-cell lymphoma, alongside their correlation with the soluble counterparts of the PD-1/PD-L1 axis.
View Article and Find Full Text PDFRhombencephalitis in an 86-year-old woman with chronic lymphocytic leukemia.
CMAJ
January 2025
Temerty Faculty of Medicine (Tilley, Kim, Lass), University of Toronto; Departments of Medicine (Silverstein) and Neurology (Masellis), Sunnybrook Health Sciences Centre, Toronto, Ont.
Differentiation of the chronic lymphocytic leukemia response to ibrutinib and acalabrutinib treatment by single-cell MALDI-TOF MS imaging.
J Pharm Biomed Anal
January 2025
Clinical Institute of Laboratory Diagnostics, University Hospital Centre Osijek, J. Huttlera 4, Osijek 31 000, Croatia; Faculty of Medicine Osijek, JJ Strossmayer University of Osijek, J. Huttlera 4, Osijek 31 000, Croatia. Electronic address:
Ibrutinib and acalabrutinib, Bruton's tyrosine kinase inhibitors (BTKi) used for chronic lymphocytic leukemia (CLL) treatment, aim the same target but their off-target effects are different. The aim of this study was to use single-cell MALDI TOF mass spectrometry imaging to compare the CD19+ lymphocytes' mass spectra in untreated and ibrutinib- or acalabrutinib-treated subjects in order to better understand the therapeutic effect of BTKi. 180 cells from 9 male subjects divided in 3 groups (untreated, ibrutinib-treated and acalabrutinib-treated) were analyzed using MALDI-TOF mass spectrometry analyzer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!